AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01179841 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Parent Training
Description: The 1-2 hour individual therapeutic sessions with parent training in the home or clinic (1x every week over six months) are based on our own program which is in development. This program focuses on teaching parents how to encourage social and communication skills in their toddlers and also provides comprehensive information about development. Sessions will focus on knowledge of autism, current access to services, general knowledge of strategies used to facilitate child development, advocacy, knowledge of how to access services, and coping strategies.
Study NCT01179841 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Parent Training
Description: In the once-a-week 1 to 2 hour parent training/enrichment, we will ask parents to target specific play and care routines in which they may stimulate their child's development in the ways identified by the therapist. These stimulation times may be provided by the parents, other family members, friends, volunteers or hired assistants. Parents will be encouraged to have their child in direct skill-enhancing engagement for 1-2 hour per day. The therapist will work with the family to identify times during the day that best lend themselves to accomplishing this goal.
Study NCT02952846 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Algorithm for tapering og analgosedation
Description: Algorithm for tapering og analgosedation
Study NCT03408470 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TD-1473 oral capsule
Description: (Intervention description included in arm description)
Study NCT03408470 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C]-TD-1473 IV bolus
Description: (Intervention description included in arm description)
Study NCT03408470 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C]-TD-1473 Oral Capsule
Description: (Intervention description included in arm description)
Study NCT03087097 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fecal Microbiota Transplantation
Description: Fecal microbiota delivered by rectal catheter enema in participants 12-60 months of age with malnutrition (MAM or SAM) who are in the rehabilitation phase of treatment and have failed to respond to at least 4 weeks of standard therapy.
Study NCT04143594 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Lenacapavir
Description: Tablets administered without regard to food
Study NCT04143594 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: F/TAF
Description: Tablets administered without regard to food
Study NCT04143594 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Subcutaneous Lenacapavir
Description: Administered in the abdomen via subcutaneous injections
Study NCT00733577 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SB756050
Description: doses are planned to be 15mg to 600mg doses may be altered based on plasma concentrations
Study NCT02636751 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 12-week prehabilitation program
Description: stretching, strengthening, proprioceptive exercises of the lower limb and cardiovascular training using low-impact activities
Study NCT04143594 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAF
Description: Tablets administered without regard to food
Study NCT04143594 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIC
Description: Tablets administered without regard to food
Study NCT04143594 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: B/F/TAF
Description: Tablets administered without regard to food
Study NCT00110227 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 12-week Tai Chi Program
Description: 24 tai chi sessions. 2 sessions/week for 12 weeks.
Study NCT00110227 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: 12-week Education Program
Description: 24 Educational sessions. 2 sessions/week for 12 weeks.
Study NCT00831974 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: masitinib (AB1010)
Description: 3 mg/kg/day
Study NCT00831974 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: masitinib (AB1010)
Description: 6 mg/kg/day
Study NCT00733239 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2-4 of the drugs listed below
Description: Cycloserine: 500, 675, 750 mg oral capsule may possibly be given Diltiazem: 30, 60, 120 mg oral capsule may possibly be given Gabapentin: 100, 200, 400 mg oral capsule may possibly be given Isradipine: 5, 10 mg oral capsule may possibly be given Naloxone: 0.15 mg/70 kg or 0.2 mg I.M. injection may possibly be given Nifedipine: 5, 10, 20 mg oral capsule may possibly be given Placebo (sugar pill or microcrystalline cellulose): oral capsule may possibly be given Saline: I.M. injection may possibly be given Verapamil: 30, 60, 120 mg oral capsule may possibly be given
Study NCT02063945 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylphenidate
Description: As stated in arm/group
Study NCT02063945 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Risperidone
Description: As stated in arm/group
Study NCT03190668 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bolus dose of Cefazolin
Description: Mode of Cefazolin administration will be a intermittent bolus
Study NCT03190668 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Continuous Cefazolin drip
Description: Mode of Cefazolin administration will be a continuous drip
Study NCT03190668 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Paraspinal muscle microdialysis catheters
Description: Two dialysis probes will be inserted into a paraspinal muscle
Study NCT03190668 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Subcutaneous microdialysis catheters
Description: Two dialysis probes will be inserted into a paraspinal subcutaneous region
Study NCT00831714 — intervention group
Intervention type: DRUG
Intervention: Rivaroxaban (Xarelto, BAY59-7939)
Description: Female and male patients, who are at least 18 years of age and will undergo elective hip or knee arthroplasty, after the decision for VTE prophylaxis with Rivaroxaban has been made
Study NCT00831714 — intervention group
Intervention type: DRUG
Intervention: Standard care treatment for VTE prophylaxis
Description: Female and male patients, who are at least 18 years of age and will undergo elective hip or knee arthroplasty, after the decision for a pharmacologic VTE prophylaxis treatment other than rivaroxaban has been made
Study NCT02101931 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amino levulinic Acid
Description: The bladder cancer patients is required to swallow a chemical called Amino levulinic Acid, about 10mg/kg body weight. 5ml of blood and one urine samples will be taken before using Amino levulinic Acid. The patient must drink water then the urine will be collected after 4, 8 and 12 hours of taking ALA and the samples will be analyzed by photodynamic diagnostic procedure. ALA gets metabolized into certain types of porphyrins which selectively bind on to the tumor tissues (for a longer time than the normal tissues).
Study NCT02416128 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Euphrasia
Description: 1 drop in the treated eye QID X 10 days
Study NCT02416128 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisolone acetate
Description: 1 drop in the treated eye QID X 10 days
Study NCT03152331 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Receptive Awareness Training
Description: Two 12-minute learning sessions will be conducted for each learning day. Separate instructions will be provided before session 1 and before session 2 to facilitate receptive awareness. The participant is seated in front of a BIS monitor and learns that the BIS number will decrease when in a state of receptive awareness. The trainee will learn to use attentional flexibility in daily activities and adopt willful attention (focal concentration) alternatively with receptive awareness (relaxed attention), as a situation dictates.
Study NCT00877409 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Benzoyl Peroxide 5% and Sulphur 2%
Description: The product will be applied topically forming a thin layer, 1 time a day (at night) throughout the area affected by lesions.
Study NCT00877409 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle of Acnase
Description: The product will be applied topically forming a thin layer, 1 time a day (at night) throughout the area affected by lesions.
Study NCT03199482 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone Oral Tablet
Description: single dose of tablet 0.5 mg dexamethasone given to patients before starting of root canal treatment by 30 minutes or placebo
Study NCT03199482 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administrated 30 minutes before start of root canal treatment
Study NCT01249924 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: auto-titrated CPAP
Description: Patients will be treated with auto-CPAP preoperatively for 2-3 nights preoperatively and 5 nights postoperatively during their sleep.
Study NCT01249924 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Control
Description: Patients in this group will receive routine care, undergo sleep study on the third postoperative night and be monitored by a pulse oximeter for oxygen saturation level for 2-3 nights preoperatively and 5 nights postoperatively during their sleep.
Study NCT00006007 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine hydrochloride
Study NCT00006007 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pemetrexed disodium
Study NCT02347891 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belimumab
Description: Randomized phase: Week 0 - Week 40
Study NCT02347891 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Randomized phase: Week 0 - Week 40
Study NCT03207542 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daratumumab
Description: 16 mg/kg by vein weekly for the first 2 cycles (8 weeks) of treatment, followed by every 2 weeks for 4 cycles (or 16 weeks) and then every 4 weeks until progression or up to 1 year of treatment whichever comes earlier.
Study NCT05195684 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: imaginal probe
Description: trauma and nightmare imaginal probe/challenge for which psychophysiological and CNS responses are recorded
Study NCT01047826 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Minimally Invasive Plate Osteosynthesis
Description: Fractures well be treated with locked plates using M.I.P.O. Technique
Study NCT01047826 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: intramedullary tibial Nailing
Description: Fractures well be fixed using intramedullary nails
Study NCT02977325 — intervention group
Intervention type: OTHER
Intervention: water cure
Study NCT05246059 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Olfactory Training
Description: Sniffin' Sticks (Duft-Quartett, Burghart Messtechnik, GmbH, Germany)
Study NCT01335074 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temsirolimus + Sorafenib
Description: 200mg bid Sorafenib + 15, 20 or 25 mg Temsirolimus
Study NCT00070382 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: darbepoetin alfa
Description: darbepoetin alfa administered at a dose of 200ug once every 2 weeks over a 16-week treatment period
Study NCT00070382 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: epoetin alfa
Description: epoetin alfa administered at a dose of 40,000U once every week over a 16-week treatment period
Study NCT05167370 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amifostine
Description: Amifostine (Ethyol) 1125 mg/m2 will be given intravenously daily over 5 minutes starting 30 minutes prior to chemotherapy (melphalan or thiotepa) on days -5, -4, -3, -2, and on day -1 twenty four hours after prior dose of amifostine.
Study NCT04749654 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The Salivary pH measured
Description: The saliva samples were obtained at 10-12 a.m. from all children. The saliva was collected into plastic cylinders and the salivary pH was measured with a pH meter (Compact pH meter B-212 twin pH, HORIBA, Osaka, Japan).
Study NCT04749654 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The saliva flow rate was measured
Description: The saliva flow rate was estimated by during the first 30 s of paraffin chewing. The saliva was collected into plastic cylinders for a period of 5 minutes. Afterward, the saliva were weighed with a in a precision balance (Mettler PC 400, Zurich, Switzerland) and the flow rate was computed in gms/ml.
Study NCT02636751 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Walking aid adjustment
Description: Walking aid adjustment
Study NCT04749654 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Streptococcus mutans and Lactobacillus counts in saliva were measured
Description: The saliva samples were obtained according to described above. Numbers of colony-forming units (CFU) of S. mutans were counted on TSY20B agar and Lactobacilli were counted on Rogosa agar.
Study NCT03046901 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vancomycin
Description: Vancomycin belongs to the family of medicines called antibiotics.When taken by mouth, is used to treat Clostridium difficile-associated diarrhea (also called C diff). C diff is a type of bacteria that causes severe diarrhea. Oral Vancomycin is also used to treat enterocolitis caused by a certain bacteria (e.g., Staphylococcus aureus). Subjects enrolled in the study will take 500 mg capsule, 3 times per day for 3-12 weeks.
Study NCT00471718 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-751
Description: Phase I:~Cohort \| Number of Patients \|Dose (mg) ABT-751 (BID)~* -1 \| 3-6 \|100 mg BID~* 1 \| 3-6 \|125 mg BID~* 2 \| 3-6 \|150 mg BID~* 3 \| 3-6 \|175 mg BID~* 4 \| 3-6 \|200 mg BID~Phase II:~Patients receive ABT-751 at 125mg po BID for 7 days on, 7 days off (X2) for a 28 day cycle
Study NCT01990196 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: degarelix
Description: Every 4-week Treatment: A starting dose of 240 mg of Degarelix is taken subcutaneously (SQ) -placed under the skin by injection- the first month. Doses continue every 4 weeks at 80 mg SQ.~Dose for a drug may have to be modified based on development of adverse events on a case by case basis as per the judgment of treating physician.
Study NCT01990196 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: enzalutamide
Description: Once Daily Treatment: A starting dose of 160 mg of Enzalutamide is taken by mouth once daily.~Dose for a drug may have to be modified based on development of adverse events on a case by case basis as per the judgment of treating physician.
Study NCT01990196 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: trametinib
Description: Once Daily Treatment: If randomized into Group 2, then 2mg of Trametinib is taken by mouth daily.~Dose for a drug may have to be modified based on development of adverse events on a case by case basis as per the judgment of treating physician
Study NCT01990196 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dasatinib
Description: Once Daily Treatment: If randomized into Group 3, then 100mg of Dasatinib is taken by mouth daily.~Dose for a drug may have to be modified based on development of adverse events on a case by case basis as per the judgment of treating physician
Study NCT02877394 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Squatting Assist Device
Description: The Squatty Potty is a 7 inch tall stool to assist subjects in maintaining a squatting position while using a toilet. While sitting on the toilet, the subject supports her feet on the Squatty Potty.
Study NCT02877394 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Squatting Assist Device
Description: This stool will be 2 inches tall and be similar in appearance to the Squatty Potty. While sitting on the toilet, the subject supports her feet on the 2 inch high stool.
Study NCT03898479 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CTP-543
Description: Twice daily dosing
Study NCT04158882 — intervention group
Intervention type: OTHER
Intervention: Routine medical record data collection
Description: The study will collect routine medical record data from the electronic medical record system, other electronic databases, and paper charts.
Study NCT01613222 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pulse oximetry
Description: Pulse oximetry measurement using SpO2 sensors, patient monitors, co-oximeters, and various modules.
Study NCT01976364 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tofacitinib
Description: Tofacitinib 5 mg tablet twice daily
Study NCT01976364 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tofacitinib
Description: Tofactinib 10 mg tablet twice daily
Study NCT01976364 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Methotrexate 7.5-20 mg weekly
Study NCT01976364 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Methotrexate
Description: Placebo to match active methotrexate orally once a week
Study NCT03839290 — intervention group
Intervention type: PROCEDURE
Intervention: Early neonatal cheiloplasty
Study NCT01556568 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEK162
Study NCT03624062 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: MAS-1 adjuvanted Insulin B-chain
Description: MER3101 (MAS-1 adjuvanted insulin B chain (IBC)), is a white, free-flowing 30:70 (w/w) water-in-oil (W/O) emulsion. MER3101 contains in the aqueous (disperse) phase 33, 109, or 327 µg per 0.25 mL dose of IBC (Drug Substance) and the oil (continuous) phase is comprised of MAS-1 oil vehicle.
Study NCT03896737 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daratumumab plus Velcade Cyclophosphamide Dexamethasone
Description: To compare Dara-VCd versus VTd as pre transplant induction and post transplant consolidation, both followed by a maintenance phase with Ixazomib alone or in combination with Daratumumab, in newly diagnosed Multiple Myeloma (MM) young patients eligible for autologous stem cell transplantation.
Study NCT03896737 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Velcade Thalidomide Dexamethasone
Description: To compare Dara-VCd versus VTd as pre transplant induction and post transplant consolidation, both followed by a maintenance phase with Ixazomib alone or in combination with Daratumumab, in newly diagnosed Multiple Myeloma (MM) young patients eligible for autologous stem cell transplantation.
Study NCT05887570 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Educational intervention
Description: intervention through extra education, modules, instruction on models
Study NCT05887570 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control - Regular Instruction
Description: participants receive usual training
Study NCT02000336 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisolone
Description: To compare two standard p.o. GC starting dosages and the non-use of GCs in the treatment of patients with early active RA on the background of the established 'anchor' therapy with methotrexate (MTX).
Study NCT02000336 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01937910 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: TRAIT Task
Description: Increased paretic arm will be manipulated through the performance of a semi-immersive virtual reality-based intercept and release task called TRAIT (TRack And Intercept Task), which is performed in an interactive environment. TRAIT employs an open source Kinect sensor, which tracks 3-D joint movement. Participants are asked to control an on-screen icon using movements of their paretic arm to intercept a moving object as it emerges from the side of a computer screen. Once intercepted, they must accurately throw the object to hit a target. Participants move up through 10 levels of the game as their skill improves. Participants will complete 10 TRAIT training sessions in 4 weeks for a total of 10,000 experimental movements.
Study NCT01937910 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TRAIT Task
Description: Increased paretic arm will be manipulated through the performance of a semi-immersive virtual reality-based intercept and release task called TRAIT (TRack And Intercept Task), which is performed in an interactive environment. TRAIT employs an open source Kinect sensor, which tracks 3-D joint movement. Participants are asked to control an on-screen icon using movements of their paretic arm to intercept a moving object as it emerges from the side of a computer screen. Once intercepted, they must accurately throw the object to hit a target. Participants move up through 10 levels of the game as their skill improves. Participants will complete 10 TRAIT training sessions in 4 weeks for a total of 10,000 experimental movements.
Study NCT04995250 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: corrective exercise training for knee
Description: All patients received 12 weeks (3 days per week) physiotherapy sessions with hot pack, TENS and Ultrasound session for 10 mints and knee isometric, quad strengthening, adductor and abductor strengthening, calf stretch, hamstring stretch, Maitland mobilization, Unconventional Corrective knee exercise protocol treatment: standing on one extremity, up and down on bosu exercise, walking to lateral direction, walking to anterio-posterior direction, walking to anterio-posterior and lateral for 20 mints. Data were collected at baseline, at week 4 and at post treatment (week 12).
Study NCT02912260 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MGL-3196